40 results on '"Ye, Xin"'
Search Results
2. Microwave ablation treatment for medically inoperable stage I non-small cell lung cancers: long-term results
- Author
-
Ni, Yang, Huang, Guanghui, Yang, Xia, Ye, Xin, Li, Xiaoguang, Feng, Qingliang, Li, Yongjie, Li, Wenhong, Wang, Jiao, Han, Xiaoying, Meng, Min, Zou, Zhigeng, and Wei, Zhigang
- Published
- 2022
- Full Text
- View/download PDF
3. Dynamic Changes in the Immune Microenvironment in Tumor-Draining Lymph Nodes of a Lewis Lung Cancer Mouse Model After Microwave Ablation.
- Author
-
Sang, Jing, Liu, Peng, Wang, Meixiang, Xu, Fengkuo, Ma, Ji, Wei, Zhigang, and Ye, Xin
- Subjects
REGULATORY T cells ,CYTOTOXIC T cells ,KILLER cells ,T cells ,DENDRITIC cells - Abstract
Purpose: Microwave ablation (MWA) is a minimally invasive technique for treating lung cancer. It can induce immune response; however, its effect on the immune microenvironment in tumor-draining lymph nodes (TdLN) is not well understood. This study aims to identify changes in the immune microenvironment in TdLN following MWA in a Lewis lung cancer (LLC) mouse model. Methods: LLC mouse model was established and followed by MWA. TdLN were collected at various time points, including pre-MWA and days 1, 2, 4, and 8 post-MWA. Flow cytometry was used to determine the frequencies of CD4
+ T cells, CD8+ T cells, regulatory T (Treg) cells, natural killer (NK) cells, dendritic cells (DCs) and other immune cells in the TdLN. Certain cytokines were also detected. Results: Compared with pre-MWA, the frequency of CD4+ T cells significantly increased from day 1 to day 8 post-MWA. The frequency of CD8+ T cells decreased significantly on days 2 and 4, but no significant changes occurred on days 1 and 8. Significant decreases in the frequencies of Treg cells and Klrg1+ Treg cells were observed from day 1 to day 4. On days 4 and 8, there was a significant increase in the frequency of NK cells. The frequency of resident cDC2 significantly increased on day 4, whereas CD11b+ migratory cDCs increased on day 1. Additionally, on day 4, a notable rise was observed in the frequency of NK cells secreting IFN-γ, while on day 8, there was a significant increase in the frequency of CD8+ T cells secreting both IFN-γ and TNF-α. Conclusion: MWA of lung cancer can alter the immune microenvironment in the TdLN, triggering immune responses. These changes are particularly evident and intricate within the initial 4 days post-MWA. Treatment combined with MWA within a certain period may significantly enhance anti-tumor immunity. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
4. Microwave ablation plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer: a multicenter, randomized, controlled, phase III clinical trial
- Author
-
Wei, Zhigang, Yang, Xia, Ye, Xin, Feng, Qingliang, Xu, Yanjun, Zhang, Licheng, Sun, Wenqiao, Dong, Yuting, Meng, Qi, Li, Tao, Wang, Chuntang, Li, Guangxu, Zhang, Kaixian, Li, Peishun, Bi, Jingwang, Xue, Guoliang, Sun, Yahong, Sheng, Lijun, Liu, Bin, Yu, Guohua, Ren, Haipeng, Wang, Junye, Sun, Lijun, Chen, Shaoshui, Geng, Dianzhong, Zhang, Benhua, Xu, Xin, Zhang, Liangming, Sun, Dengjun, Xu, Xinglu, Diao, Cunqi, Huang, Guanghui, Li, Wenhong, Han, Xiaoying, Wang, Jiao, Meng, Min, Ni, Yang, Zheng, Aimin, Fan, Weijun, Li, Yuliang, Li, Fan, Fan, Hua, Zou, Zhigeng, Li, Qingyu, and Tian, Hui
- Published
- 2020
- Full Text
- View/download PDF
5. Microwave ablation for non-small cell lung cancer with synchronous solitary extracranial metastasis
- Author
-
Ni, Yang, Ye, Xin, Yang, Xia, Huang, Guanghui, Li, Wenhong, Wang, Jiao, Han, Xiaoying, Wei, Zhigang, Meng, Min, and Zou, Zhigeng
- Published
- 2020
- Full Text
- View/download PDF
6. Microwave ablation as local consolidative therapy for patients with extracranial oligometastatic EGFR-mutant non-small cell lung cancer without progression after first-line EGFR-TKIs treatment
- Author
-
Ni, Yang, Ye, Xin, Yang, Xia, Huang, Guanghui, Li, Wenhong, Wang, Jiao, Han, Xiaoying, Wei, Zhigang, and Meng, Min
- Published
- 2020
- Full Text
- View/download PDF
7. Local Thermal Ablation with Continuous EGFR Tyrosine Kinase Inhibitors for EGFR-Mutant Non-small Cell Lung Cancers that Developed Extra-Central Nervous System (CNS) Oligoprogressive Disease
- Author
-
Ni, Yang, Liu, Baodong, Ye, Xin, Fan, Weijun, Bi, Jingwang, Yang, Xia, Huang, Guanghui, Li, Wenhong, Wang, Jiao, Han, Xiaoying, Wei, Zhigang, and Meng, Min
- Published
- 2019
- Full Text
- View/download PDF
8. Advanced non small cell lung cancer: response to microwave ablation and EGFR Status
- Author
-
Wei, Zhigang, Ye, Xin, Yang, Xia, Huang, Guanghui, Li, Wenhong, Wang, Jiao, Han, Xiaoying, Meng, Min, and Ni, Yang
- Published
- 2017
- Full Text
- View/download PDF
9. Computed tomography-guided percutaneous microwave ablation combined with osteoplasty for palliative treatment of painful extraspinal bone metastases from lung cancer
- Author
-
Wei, Zhigang, Zhang, Kaixian, Ye, Xin, Yang, Xia, Zheng, Aimin, Huang, Guanghui, and Wang, Jiao
- Published
- 2015
- Full Text
- View/download PDF
10. Targeted percutaneous microwave ablation at the pulmonary lesion combined with mediastinal radiotherapy with or without concurrent chemotherapy in locally advanced non-small cell lung cancer evaluation in a randomized comparison study
- Author
-
Xu, Xinglu, Ye, Xin, Liu, Gang, and Zhang, Tingping
- Published
- 2015
- Full Text
- View/download PDF
11. Microwave ablation plus chemotherapy improved progression-free survival of advanced non-small cell lung cancer compared to chemotherapy alone
- Author
-
Wei, Zhigang, Ye, Xin, Yang, Xia, Huang, Guanghui, Li, Wenhong, Wang, Jiao, and Han, Xiaoying
- Published
- 2015
- Full Text
- View/download PDF
12. Microwave Ablation in Combination with Chemotherapy for the Treatment of Advanced Non-Small Cell Lung Cancer
- Author
-
Wei, Zhigang, Ye, Xin, Yang, Xia, Zheng, Aimin, Huang, Guanghui, Li, Wenhong, Ni, Xiang, Wang, Jiao, and Han, Xiaoying
- Published
- 2015
- Full Text
- View/download PDF
13. Early enlarging cavitation after percutaneous microwave ablation of primary lung cancer.
- Author
-
Wang, Nan, Xu, Jingwen, Cao, Pikun, Li, Zhichao, Xue, Guoliang, Hu, Yanting, Zhang, Haitao, Han, Cuiping, Zhao, Wenhua, Yang, Xia, Wei, Zhigang, and Ye, Xin
- Subjects
CAVITATION ,LUNG cancer ,MICROWAVES ,BRONCHIAL fistula ,BRONCHI - Abstract
This retrospective study assessed the incidence rate, risk factors, and clinical course of early enlarging cavitation after percutaneous microwave ablation (MWA) of primary lung cancer (PLC). This study included 557 lesions of 514 patients with PLC who underwent CT-guided percutaneous MWA between 1 January 2018 and 31 December 2021. Of these patients, 29 developed early enlarging cavitation and were enrolled in the cavity group, and 173 were randomly enrolled in the control group. Early enlarging cavitation of the lung was defined as the development of a cavity ≥30 mm within 7 days after MWA. Overall, 31 (5.57%, 31/557 tumors) early enlarging cavitations occurred at an average of 5.83 ± 1.55 d after MWA. The risk factors were lesion contact with a large vessel (diameter ≥3 mm), lesion contact with the bronchus (diameter ≥2 mm), and a large ablated parenchymal volume. The cavity group had a higher incidence rate of delayed hydropneumothorax (12.9%) and bronchopleural fistula (9.68%) than the control group, resulting in a longer hospitalization (9.09 ± 5.26 days). Until Dec 31, 2022, 27 cavities disappeared after a mean of 217.88 ± 78.57 d (range, 111–510 d), two persisted, and two were lost to follow-up. Early enlarging cavitation occurred in 5.57% PLC cases that underwent MWA, causing serve complications and longer hospitalization. The risk factors were ablated lesion contact with large vessels and bronchi, as well as a larger ablated parenchymal volume. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
14. Synchronous computed tomography-guided percutaneous biopsy and microwave ablation for highly suspicious malignant lung ground-glass opacities adjacent to mediastinum.
- Author
-
Wang, Nan, Xu, Jingwen, Xue, Guoliang, Han, Cuiping, Zhang, Haitao, Zhao, Wenhua, Li, Zhichao, Cao, Pikun, Hu, Yanting, Wei, Zhigang, and Ye, Xin
- Subjects
MEDIASTINUM ,VENTRICULAR arrhythmia ,MANN Whitney U Test ,BIOPSY ,MICROWAVES - Abstract
This retrospective study aimed to assess the safety and efficacy of synchronous biopsy and microwave ablation (MWA) for highly suspected malignant lung ground-glass opacities (GGOs) adjacent to the mediastinum (distance ≤10 mm). Ninety patients with 98 GGOs (diameter range, 6–30 mm), located within 10 mm of the mediastinum, underwent synchronous biopsy and MWA at a single institution from 1 May 2020, to 31 October 2021 and were enrolled in this study. Synchronous biopsy and MWA involving the completion of the biopsy and MWA in a single procedure was performed. Safety, technical success rate, and local progression-free survival (LPFS) were evaluated. The risk factors for local progression were calculated using the Mann–Whitney U test. The technical success rate was 97.96% (96/98 patients). The LPFS rates at 3, 6, and 12 months were 95.0%, 90.0%, and 82.0%, respectively. The diagnostic rate of biopsy-proven malignancy was 72.45% (n = 71/98). Invasion of lesions into the mediastinum was a risk factor for local progression (p = 0.0077). The 30-day mortality rate was 0. The major complications were pneumothorax (13.27%), ventricular arrhythmias (3.06%), pleural effusion (1.02%), hemoptysis (1.02%), and infection (1.02%). Minor complications included pneumothorax (30.61%), pleural effusion (24.49%), hemoptysis (18.37%), ventricular arrhythmias (11.22%), structural changes in adjacent organs (3.06%), and infection (3.06%). Synchronous biopsy and MWA was effective for treating GGOs adjacent to the mediastinum without severe complications (Society of Interventional Radiology classification E or F). Invasion of lesions into the mediastinum was identified as a risk factor for local progression. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. Computed tomography findings, associated factors, and management of pulmonary nodules in 54,326 healthy individuals.
- Author
-
Liang, Xinyu, Kong, Yongmei, Shang, Hui, Yang, Mingxin, Lu, Wenjing, Zeng, Qingshi, Zhang, Guang, and Ye, Xin
- Subjects
PULMONARY nodules ,COMPUTED tomography ,PATIENTS ,LUNG diseases ,LUNG cancer - Abstract
Introduction: To investigate the pulmonary nodules detected by low-dose computed tomography (LDCT), identified factors affecting the size and number of pulmonary nodules (single or multiple), and the pulmonary nodules diagnosed and management as lung cancer in healthy individuals. Methods: A retrospective analysis was conducted on 54,326 healthy individuals who received chest LDCT screening. According to the results of screening, the detection rates of pulmonary nodules, grouped according to the size and number of pulmonary nodules (single or multiple), and the patients' gender, age, history of smoking, hypertension, and diabetes were statistically analyzed to determine the correlation between each factor and the characteristics of the nodules. The pulmonary nodules in healthy individuals diagnosed with lung cancer were managed with differently protocols. Results: The detection rate of pulmonary nodules was 38.8% (21,055/54,326). The baseline demographic characteristics of patients with pulmonary nodules were: 58% male and 42% female patients, 25.7% smoking and 74.3% nonsmoking individuals, 40–60 years old accounted for 49%, 54.8% multiple nodules, and 45.2% single nodules, and ≤5-mm size accounted for 80.4%, 6–10 mm for 18.2%, and 11–30 mm for 1.4%. Multiple pulmonary nodules were more common in hypertensive patients. Diabetes is not an independent risk factor for several pulmonary nodules. Of all patients with lung nodules, 26 were diagnosed with lung cancer, accounting for 0.1% of all patients with pulmonary nodules, 0.6% with nodules ≥5 mm, and 2.2% with nodules ≥8 mm, respectively. Twenty-six patients with lung cancer were treated with surgical resection (57.7%), microwave ablation (MWA, 38.5%), and follow-up (3.8%). Conclusions: LDCT was suitable for large-scale pulmonary nodules screening in healthy individuals, which was helpful for the early detection of suspicious lesions in the lung. In addition to surgical resection, MWA is an option for early lung cancer treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
16. Microwave ablation of the lung: Comparison of 19G with 14G and 16G microwave antennas in ex vivo porcine lung.
- Author
-
Cai, Hongchao, Tian, Hui, Wei, Zhigang, and Ye, Xin
- Subjects
MICROWAVE antennas ,LUNGS ,TECHNOLOGICAL innovations ,MICROWAVES ,ANTENNAS (Electronics) - Abstract
Background: Percutaneous image-guided thermal ablation has an increasing role in the treatment of primary and metastatic lung tumors. Although microwave ablation (MWA) has emerged advantageous as a new ablation technology, more research is needed to improve it. This study aims to investigate the ablation zone of three microwave antennas in ex vivo porcine lung. Materials and Methods: In the ex vivo standard model and porcine lung model, MWA was performed in three power output settings (50 W, 60 W, and 70 W) for 3, 6, 9, and 12 min using three microwave antennas, with outer diameter of 1.03 mm (19G), 1.6 mm (16G), and 2.0 mm (14G). A total of 108 and 216 sessions were performed (3 or 6 sessions per time setting with the 14G, 16G, and 19G microwave antennas). After the MWA was complete, we evaluated the shape and extent of the coagulation zone and measured the maximum long-axis (along the needle axis; length [L]) and maximum short-axis (perpendicular to the needle; diameter [D]) of the ablation zones using a ruler; subsequently, the sphericity index (L/D) was calculated. The sphericity index can be simplified as long-axis/short-axis. Results: In the ex vivo standard model study, the long- and short-axis diameters and sphericity indices were not statistically different between the 14G, 16G, and 19G groups. In the ex vivo porcine lung study, the long- and short-axis diameters did not differ statistically between the 14G, 16G, and 19G groups (P < 0.05 each). The sphericity index for the 19G microwave antenna was higher than the sphericity indices for the 14G and 16G microwave antennas (P < 0.05); however, the index for the 14G microwave antenna was not statistically different than that for the 16G microwave antenna (P > 0.05). Conclusions: The ablation zone of the 19G antenna was the same as those of the 14G and 16G antennas in vitro. Thus, the 19G antenna may reduce the incidence of complications in lung tumor ablation. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
17. Safety and efficacy of microwave ablation for lung cancer adjacent to the interlobar fissure.
- Author
-
Wang, Nan, Xu, Jingwen, Wang, Gang, Xue, Guoliang, Li, Zhichao, Cao, Pikun, Hu, Yanting, Cai, Hongchao, Wei, Zhigang, and Ye, Xin
- Subjects
PNEUMONIA ,PLEURAL effusions ,LUNG tumors ,MICROWAVES ,RETROSPECTIVE studies ,SURGICAL complications ,TREATMENT effectiveness ,SURVIVAL analysis (Biometry) ,PROGRESSION-free survival ,ABLATION techniques ,PATIENT safety ,PNEUMOTHORAX - Abstract
Background: This retrospective study aimed to assess the safety and efficacy of microwave ablation for lung tumors adjacent to the interlobar fissures. Methods: From May 2020 to April 2021, 59 patients with 66 lung tumors (mean diameter, 16.9 ± 7.7 mm; range, 6–30 mm) adjacent to the interlobar fissures who underwent microwave ablation at our institution were identified and included in this study. Based on the relationship between the tumor and the interlobar fissure, tumors can be categorized into close to the fissure, causing the fissure, and involving the fissure. The complete ablation rate, local progression‐free survival, complications, and associated factors were analyzed. Results: All 66 histologically proven tumors were treated using computed tomography‐guided microwave ablation. The complete ablation rate was 95.5%. Local progression‐free survival at 3, 6, 9, and 12 months were 89.4%, 83.3%, 74.2%, and 63.6%, respectively. The complications included pneumothorax (34.8%), pleural effusion (24.2%), cavity (18.2%), and pulmonary infection (7.6%). There were statistical differences in the incidence of pneumothorax, cavity, and delayed complications between the groups with and without antenna punctures through the fissure. Conclusions: Microwave ablation is a safe and effective treatment for lung tumor adjacent to the interlobar fissure. Antenna puncturing though the interlobar fissure may be a potential risk factor for pneumothorax, cavity, and delayed complications. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
18. Microwave ablation for lung cancer patients with a single lung: Clinical evaluation of 11 cases
- Author
-
Yang, Xia, Ye, Xin, Zhang, Licheng, Geng, Dianzhong, Du, Zhenli, Yu, Guohua, Ren, Haipeng, Wang, Jiao, Huang, Guanghui, Wei, Zhigang, Ni, Yang, Li, Wenhong, and Han, Xiaoying
- Subjects
Male ,Hemoptysis ,Lung Neoplasms ,Pneumothorax ,Hemorrhage ,Original Articles ,Middle Aged ,NSCLC ,Disease-Free Survival ,Pleural Effusion ,Microwave ablation ,single lung ,Catheter Ablation ,Humans ,Original Article ,Female ,Neoplasm Recurrence, Local ,Microwaves ,Pneumonectomy ,Tomography, X-Ray Computed ,Lung ,Aged ,Retrospective Studies - Abstract
Background The study was conducted to retrospectively evaluate the safety and effectiveness of computed tomography (CT)‐guided percutaneous microwave ablation (MWA) for peripheral non‐small cell lung cancer (NSCLC) in 11 patients with a single lung after pneumonectomy. Methods From May 2011 to March 2015, 11 single‐lung patients (8 men and 3 women; mean age 60.3 years, range 46–71) with peripheral NSCLC underwent 12 sessions of MWA. Eleven tumors measuring 13–52 mm (mean 30.2 mm) were treated. Follow‐up was performed via CT scan at 1, 3, 6, 12, 18, and 24 months after the procedure and annually thereafter. Clinical outcomes were evaluated and complications after MWA were summarized. Results At a median follow‐up period of 20 months (range 6–38), four patients showed evidence of local recurrence at a rate of 36.4% (4/11). Median overall survival was 20 months. The overall survival rates at one, two, and three years after MWA were 88.7%, 63.6%, and 42.3%, respectively. Complications after MWA included pneumothorax (33.3%), hemoptysis (33.3%), intrapulmonary bleeding (25%), pleural effusion (16.7%), and pulmonary infection (8.3%). None of the patients died during the procedure or in the 30 days after MWA. Conclusion CT‐guided percutaneous MWA is safe and effective for the treatment of peripheral NSCLC in patients with a single lung after prior pneumonectomy.
- Published
- 2018
19. Microwave ablation of non-small cell lung cancer tumors changes plasma levels of cytokines IL-2 and IFN-γ.
- Author
-
Xu, Hui, Tan, Xiaojing, Kong, Yongmei, Huang, Yahan, Wei, Zhigang, and Ye, Xin
- Subjects
TREATMENT of lung tumors ,LUNG cancer ,CYTOKINES ,INTERLEUKIN-2 ,MICROWAVES ,CELL physiology ,RETROSPECTIVE studies ,INTERFERONS ,TUMOR necrosis factors - Abstract
Background: Combined therapy with immune checkpoint inhibitors (ICIs) and microwave ablation (MWA) is known to improve outcome in non-small cell lung cancer (NSCLC). However, the mechanism underlying the synergistic effect of these two treatments is unknown. Tumor immune microenvironment is known to affect the efficacy of ICI. Therefore, in the present study, we evaluated changes in the levels of peripheral cytokines at 48 h and 1-month post-ablation in patients with NSCLC.Materials and Methods: A total of 44 patients with primary NSCLC were retrospectively enrolled. All patients underwent MWA of the primary tumors. Plasma samples were collected pre- and post-ablation to examine the levels of various cytokines, including interleukin (IL)-2, IL-4, IL-6, IL-10, IL-12, IL-17, tumor necrosis factor (TNF)-α, and interferon-gamma (IFN-γ).Results: Although the levels of the majority of cytokines remained within normal range, levels of IL-2 and IFN-γ were significantly decreased at 48 h post-ablation and increased at 1-month post-ablation. In the subgroup analyses, changes in IL-2 and IFN-γ levels were commonly identified. Moreover, the Eastern Cooperative Oncology Group status, sex, pathology type, tumor site, and tumor size were associated with cytokines' levels pre-ablation or post-ablation.Conclusion: MWA of NSCLC tumors influenced the plasma levels of cytokines IL-2 and IFN-γ. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
20. Safety and efficacy of microwave ablation to treat pulmonary nodules under conscious analgosedation with sufentanil: A single-center clinical experience.
- Author
-
Cao, Pikun, Meng, Wenjun, Xue, Guoliang, Wang, Nan, Li, Zhichao, Kong, Yongmei, Wei, Zhigang, and Ye, Xin
- Subjects
NAUSEA ,DIZZINESS ,MICROWAVES ,SUFENTANIL ,VOMITING - Abstract
Purpose: The present study was designed to evaluate the safety and efficacy of computed tomography-guided percutaneous microwave ablation (MWA) to treat pulmonary nodules under conscious analgosedation with sufentanil.Materials and Methods: February to May 2021, 124 patients with 151 pulmonary nodules were enrolled in this study. The patients underwent 124 sessions of MWA. Sufentanil (0.25 μg/kg) was injected intravenously before MWA.Results: The technical success was 100% and no procedure-related deaths. The dosage of sufentanil was 16.6 ± 3.0 μg. The mean tumor diameter in the enrolled patients was 1.3 ± 0.8 cm. The intraoperative mean numerical rating scale (NRS) was 2.2 ± 1.7. Among the patients with NRS >3, seven patients had nodules adjacent to the pleura, while in ten patients, they were not adjacent. The mean systolic, diastolic blood pressure, and heart rate of patients were 139.1 ± 23.5 mmHg, 77.8 ± 12.3, and 76.1 ± 13.4 times/min, respectively, before sufentanil injection. The mean lowest systolic, lowest diastolic blood pressure, and lowest heart rate intraoperative were 132.9 ± 22.0 mmHg, 76.1 ± 12.1, and 74.0 ± 13.5 times/min. Twenty-six patients had mild adverse events including nausea (6.45%, 8/124), dizziness (2.42%, 3/124), vomiting(4.03%, 5/124), nausea and dizziness (2.42%, 3/124), nausea with vomiting and dizziness (2.42%, 3/124), urinary retention (1.61%, 2/124) and respiratory depression (0.81%, 1/124).Conclusion: Sufentanil is a feasible, safe, and effective analgesic for MWA in patients with pulmonary nodules. It can be used for clinical promotion. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
21. Microwave ablation or plus monochemotherapy in elderly advanced non-small-cell lung cancer patients.
- Author
-
Wei, Zhigang, Li, Qingyu, Ye, Xin, Yang, Xia, Huang, Guanghui, Li, Wenhong, Wang, Jiao, and Han, Xiaoying
- Subjects
LUNG cancer prognosis ,LUNG cancer treatment ,DISEASE progression ,STATISTICS ,ACQUISITION of data methodology ,CONFIDENCE intervals ,CANCER chemotherapy ,TIME ,MULTIVARIATE analysis ,MICROWAVES ,RETROSPECTIVE studies ,CANCER patients ,TREATMENT effectiveness ,SEX distribution ,MEDICAL records ,SURVIVAL analysis (Biometry) ,DESCRIPTIVE statistics ,COMBINED modality therapy ,ABLATION techniques ,EVALUATION ,OLD age - Abstract
To evaluate the efficacy of microwave ablation (MWA) and MWA plus monochemotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC). Patients with advanced NSCLC aged ≥70 years were retrospectively enrolled. MWA was performed at the primary tumor site. The end points included progression-free survival (PFS), response to MWA and overall survival (OS). Fifty-four patients were enrolled; of these, 36 received monochemotherapy. Complete ablation was achieved in 42 patients (77.8%). The median PFS and OS were 4.9 months and 21.8 months, respectively. Univariate analyses showed that female patients had superior PFS (31.9 months [95% confidence interval (CI): 0.8–63.0]) vs. 5.0 months in male patients (95% CI: 2.0–8.0), p =.002). Female sex was associated with better OS (not reached vs. 10.8 months, 95% CI: 9.3–12.3, p =.003). Moreover, patients with primary tumor size <3.5 cm had better OS than those with tumor size ≥3.5 cm (not reached vs. 10.9 months, 95% CI: 8.2–13.6, p =.006). Multivariate analyses showed that no characteristics were independent prognostic factors of PFS, but sex and primary tumor size were independent prognostic factors of OS. MWA was effective in the treatment of elderly patients with advanced NSCLC. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
22. Image‐guided percutaneous microwave ablation of early‐stage non–small cell lung cancer.
- Author
-
Ni, Yang, Xu, Hui, and Ye, Xin
- Subjects
NON-small-cell lung carcinoma ,ABLATION techniques ,MICROWAVES ,LASER ablation ,CATHETER ablation - Abstract
Although surgical lobectomy with systematic mediastinal lymph node evaluation is considered as the "gold standard" for management of early stage non–small cell lung cancer (NSCLC), image‐guided percutaneous thermal ablation has been increasingly used for medically inoperable patients. Radiofrequency ablation (RFA) is a research‐based technique that has the most studies for medically inoperable early‐stage NSCLC. Other thermal ablation techniques used to treat pulmonary tumors include microwave ablation (MWA), cryoablation and laser ablation. MWA has several advantages over RFA including reduced procedural time, reduced heat‐sink effect, large ablation zones, decreased susceptibility to tissue impedance, and simultaneous use of multiple antennae. This review article highlights the most relevant updates of MWA for the treatment of early‐stage NSCLC, including mechanism of action, clinical outcomes, potential complications, the existing technique problems and future directions. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
23. Immune abscopal effect of microwave ablation for lung metastases of endometrial carcinoma.
- Author
-
Xu, Hui, Sun, Wenqiao, Kong, Yongmei, Huang, Yahan, Wei, Zhigang, Zhang, Licheng, Liang, Jing, and Ye, Xin
- Subjects
ENDOMETRIAL cancer ,MICROWAVES ,METASTASIS ,LUNGS ,SPONTANEOUS cancer regression ,TREATMENT of lung tumors ,CANCER treatment ,HYSTERECTOMY ,LUNG tumors ,CANCER ,TREATMENT effectiveness ,ENDOMETRIAL tumors ,COMPUTED tomography - Abstract
Increasing evidence support that microwave ablation (MWA) induces spontaneous abscopal regression of the tumor, also called as the abscopal effect. Although the abscopal effect after MWA is a rare event, several studies have suggested that this effect is the result of the activation of the immune system induced by the death of immunogenic tumor cells. Here, we have presented the case of a 65-year-old woman with primary endometrial cancer who developed bilateral pulmonary metastases. After local MWA of one lesion in her right lung, progressive regression of the other lesions in the right and left lungs was recorded. This case supports the hypothesis that the abscopal effect is attributable to the activation of the systemic immune response. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
24. Rechallenge of camrelizumab in non-small-cell lung cancer patients treated previously with camrelizumab and microwave ablation.
- Author
-
Wei, Zhigang, Yang, Xia, and Ye, Xin
- Subjects
NON-small-cell lung carcinoma ,CANCER patients ,MICROWAVES - Abstract
Camrelizumab is a programmed death receptor-1 inhibitor originally developed in China for the treatment of refractory lymphoma. It has also been effective in non-small-cell lung cancer patients. However, the rechallenge of camrelizumab was not reported previously. We report the rechallenge of camrelizumab therapy in two patients previously treated with microwave ablation (MWA) and camrelizumab. Although objective responses were achieved, camrelizumab therapy was discontinued because of the development of immune-related pneumonia (IRP). Treatment with camrelizumab was reinitiated after the patients recovered from IRP. The reoccurrence of more severe IRP necessitated additional corticosteroid therapy. The rechallenge of camrelizumab in patients treated with MWA plus camrelizumab regimen and who developed IRP should be cautious. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
25. Combined microwave ablation and antiangiogenic therapy to increase local efficacy.
- Author
-
Ni, Yang, Yang, Xia, Cui, Jian, Li, Zhichao, Yang, Pingping, Xu, Jiaju, Shan, Guanglian, and Ye, Xin
- Subjects
ANIMAL experimentation ,ANTHROPOMETRY ,COLLAGEN ,METASTASIS ,MICROWAVES ,NEOVASCULARIZATION inhibitors ,HEALTH outcome assessment ,RABBITS ,SAFETY ,SURVIVAL ,TUMORS ,ABLATION techniques ,DESCRIPTIVE statistics - Abstract
Purpose: We aim to evaluate the efficacy, safety and survival time of microwave ablation (MWA) with adjuvant antiangiogenic therapy-endostatin in animal models. Material and methods: A total of 40 rabbits successfully implanted with VX2 tumors were randomly assigned to four experimental groups: Group A underwent only microwave ablation of the tumors; Group B received only antiangiogenic drugs endostatin; Group C received endostatin immediately after MWA; Group D followed up without treatment. Results: Two months post-treatment, tumor sizes of Group A and Group C were reduced to 1.936 ± 0.373 cm
3 and 1.592 ± 0.382 cm3 , respectively. However, tumors grew to 15.091 ± 1.735 cm3 and 47.825 ± 7.664 cm3 in Group B and the control group. Three months post-treatment, tumor sizes in Group A and Group C maintained as 1.395 ± 0.394 cm3 and 1.482 ± 0.305 cm3 , significantly smaller than Group B (35.277 ± 6.019 cm3 ). All animals in the control group died, while four (40%) survived in Group B (Endo Group). The numbers of survivals in Groups A and C were seven (70%) and eight (80%), respectively. The lowest metastasis rate (2/10, 20%) was observed in Group C (combination therapy). Conclusion: The combination of MWA and antiangiogenic therapy triggered a significant reduction in the growth rate and metastases of tumors and may potentially improve survivals. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
26. A feasibility and safety study of computed tomography-guided percutaneous microwave ablation: a novel therapy for multiple synchronous ground-glass opacities of the lung.
- Author
-
Huang, Guanghui, Yang, Xia, Li, Wenhong, Wang, Jiao, Han, Xiaoying, Wei, Zhigang, Meng, Min, Ni, Yang, Zou, Zhigeng, Wen, Qiang, Dai, Jianjian, Zhang, Tiehong, and Ye, Xin
- Abstract
The present study retrospectively evaluated the feasibility, safety, and short-term efficacy of computed tomography (CT)-guided percutaneous microwave ablation (MWA) to treat multiple synchronous ground-glass opacities (GGOs) of the lung. From October 2016 to May 2019, 33 patients (9 males and 24 females, mean age: 59.6 ± 10.0 years) with multiple GGOs (103 GGOs with mean size 12.3 ± 6.3 mm) were enrolled in this study. Patients underwent 66 procedures of CT-guided percutaneous MWA. The feasibility, safety, local progression-free survival, and overall survival were evaluated. The technical success and technique efficacy rate were 100% and no MWA procedure-related deaths were reported. The median follow-up period was 18.1 (range: 6.8–37.7) months. Major complications included pneumothorax (11/66, 16.7%), pleural effusion (2/66, 3.0%), pneumonia (3/66, 4.5%), and nerve injury (1/66, 1.5%), which were well controlled by appropriate treatment. Minor complications included pneumothorax (38/66, 57.6%), pleural effusion (43/66, 65.2%), hemoptysis (13/66, 19.7%), subcutaneous emphysema (4/66, 6.1%), and hemothorax (2/66, 3.0%). Currently, all patients are alive without local progression or tumor recurrence, despite the relatively insufficient follow-up time. CT-guided percutaneous MWA for the treatment of multiple synchronous lung GGOs is feasible, safe, and efficacious over short-term follow-up. It may also be employed as an alternative approach for nonsurgical candidates. A longer follow-up is warranted to evaluate the oncologic outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
27. Safety and clinical outcomes of computed tomography‐guided percutaneous microwave ablation in patients aged 80 years and older with early‐stage non‐small cell lung cancer: A multicenter retrospective study.
- Author
-
Han, Xiaoying, Yang, Xia, Huang, Guanghui, Li, Chunhai, Zhang, Licheng, Qiao, Yuanxun, Wang, Chuntang, Dong, Yuting, Chen, Xiangming, Feng, Qingliang, Wang, Chuandai, Rong, Zhenhua, Ding, Kun, Wei, Zhigang, Ni, Yang, Wang, Jiao, Li, Wenhong, Meng, Min, and Ye, Xin
- Subjects
LUNG cancer prognosis ,SURGICAL complication risk factors ,COMPUTED tomography ,HEALTH facilities ,LUNG cancer ,MEDICAL cooperation ,PLEURA cancer ,PLEURAL effusions ,PNEUMOTHORAX ,RESEARCH ,TUMOR classification ,TREATMENT effectiveness ,RETROSPECTIVE studies ,DISEASE progression ,ABLATION techniques ,DISEASE risk factors ,OLD age - Abstract
Background: Previous studies have documented the therapeutic value of computed tomography (CT)‐guided percutaneous microwave ablation (MWA) for early‐stage non‐small cell lung cancer (NSCLC). However, few studies have focused on patients aged 80 years and older. This retrospective study aimed to evaluate the safety and clinical outcomes of CT‐guided percutaneous MWA in patients aged 80 years and older with early‐stage peripheral NSCLC. Methods: A retrospective analysis of 63 patients aged 80 years and older with cT1a‐2bN0M0 peripheral NSCLC who underwent CT‐guided percutaneous MWA was performed between January 2008 and January 2018 at 11 hospitals in Shandong Province, China. Results: The median follow‐up time was 21.0 months. The overall median survival time was 50 months. The cancer‐specific median survival time was not reached in five years. The one‐, two‐, three‐, four‐, and five‐year overall survival rates were 97.1%, 92.6%, 63.4%, 54.4%, and 32.6%, respectively. The one‐, two‐, and three‐year cancer‐specific survival (CSS) rates were 97.9%, 97.9%, and 69.4%, respectively. The four‐ and five‐year CSS rates were not achieved. A total of 14 patients (22.2%) had local progression. The one‐, two‐, three‐, four‐, and five‐year local control rates were 88.8%, 78.8%, 70.3%, 63.9%, and 63.9%, respectively. The mortality rate was 0% within 30 days after the procedure. Major complications included pneumothorax requiring drainage (21.1%), pulmonary infection (4.2%), and pleural effusions requiring drainage (2.8%). Conclusions: CT‐guided percutaneous MWA is a safe and effective modality for treating patients aged 80 years and older with early‐stage peripheral NSCLC. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
28. Camrelizumab combined with microwave ablation improves the objective response rate in advanced non-small cell lung cancer.
- Author
-
Wei, Zhigang, Yang, Xia, Ye, Xin, Huang, Guanghui, Li, Wenhong, Han, Xiaoying, Wang, Jiao, Meng, Min, Ni, Yang, Zou, Zhigeng, and Wen, Qiang
- Abstract
Aim: The present study evaluated the safety and efficacy of camrelizumab (a programmed death-1 antibody) in combination with microwave ablation (MWA) in advanced non-small cell lung cancer (NSCLC).Materials and Methods: A total of 21 patients were prospectively enrolled. MWA was performed in 25 pulmonary lesions during 21 sessions. Camrelizumab was administered 5-7 days after MWA as a dose of 200 mg, which was repeated every 2 weeks until disease progression or intolerable toxicities. The primary endpoints were safety and the objective response rate (ORR). Other endpoints included progression-free survival (PFS) and overall survival (OS).Results: The technical success rate was 100%. No treatment-associated deaths were identified. Major complications, minor complications, and side effects of MWA were observed in 9, 8, and 14 patients, respectively. The main major complications included pneumothorax, pneumonia, hemorrhage, and pleural effusion. The adverse events of camrelizumab included reactive skin capillary hyperplasia (n = 9), hypothyroidism (n = 5), pneumonia (n = 4), fatigue (n = 2), leukopenia (n = 1), and neutropenia (n = 1). Grade 2 and 3 camrelizumab adverse events were identified in eight and three patients, respectively. The ORR was 33.3%, with two patients achieving complete response and five patients achieving partial response. The median PFS was 5.1 months and OS was not reached.Conclusions: Camrelizumab administration combined with MWA was safe in the treatment of advanced NSCLC, and the combination improved the ORR of camrelizumab alone compared to previous reports. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
29. Computed tomography-guided percutaneous microwave ablation for pulmonary multiple ground-glass opacities.
- Author
-
Xue, Guoliang, Li, Zhichao, Wang, Gang, Wei, Zhigang, and Ye, Xin
- Subjects
COMPUTED tomography ,MICROWAVES ,PULMONARY nodules - Abstract
With the wide application of low-dose computed tomography (CT) and high-resolution CT, the increasing cases of pulmonary nodules are identified through routine thoracic imaging examination, many of which are presented as multiple ground-glass opacities (GGOs). The multiple GGOs could be divided into four pathological types and usually got different combined mutation patterns, suggesting that each GGO is an independent event and should be treated separately. However, there is no established guideline to the treatment of multiple GGOs so far. Here, we report a multiple GGOs case with a different mutation pattern treated by CT-guided percutaneous microwave ablation. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
30. Diagnostic ability of percutaneous core biopsy immediately after microwave ablation for lung ground-glass opacity.
- Author
-
Wang, Jiao, Ni, Yang, Yang, Xia, Huang, Guanghui, Wei, Zhigang, Li, Wenhong, Han, Xiaoying, Meng, Min, Ye, Xin, and Lei, Jiayun
- Subjects
CORE needle biopsy ,HEMOPTYSIS ,LUNGS ,BIOPSY ,LUNG infections ,MICROWAVES - Abstract
Objectives: The objective of this study is to determine the diagnostic ability of percutaneous core biopsy immediately after microwave ablation (MWA) for lung ground-glass opacity (GGO).Materials and Methods: Seventy-four patients with 74 lung GGOs were enrolled and treated with MWA. A percutaneous core needle biopsy was performed pre- and immediately post-MWA. All biopsy specimens were histologically examined by hematoxylin and eosin staining and immunostaining. Histologically, atypical adenomatous hyperplasia (AAH), adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA), and invasive adenocarcinoma (AC) were identified as positive, while chronic inflammation or normal lung tissue was identified as negative.Results: The outcomes of pre-MWA histological diagnosis were AAH (n = 4), AIS (n = 16), MIA (n = 14), AC (n = 29), chronic inflammation (n = 2), and lung tissue (n = 9) with an 85.1% (63/74) positive diagnosis rate. The outcomes of the immediately post-MWA histological diagnosis were AAH (n = 5), AIS (n = 10), MIA (n = 11), AC (n = 29), chronic inflammation (n = 1), and lung tissue (n = 18) with a 74.3% (55/74) positive diagnosis rate. There was no significant difference in the positive diagnosis rate between the pre- and immediately post-MWA groups (P = 0.10). The outcomes of the combined diagnosis of pre- and immediately post-MWA were AAH (n = 4), AIS (n = 16), MIA (n = 16), AC (n = 31), chronic inflammation (n = 2), and lung tissue (n = 5) with a positive diagnosis rate of 90.5% (67/74), which was higher than that by pre-MWA biopsy (P < 0.05). The main complications were pneumothorax (n = 45, 60.8%), hemoptysis (n = 24, 32.4%), pleural effusion (n = 39, 52.7%), and pulmonary infection (n = 10, 13.5%).Conclusions: Immediately post-MWA core biopsy has promising efficacy for histological diagnosis of lung GGOs. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
31. Efficacy and safety of microwave ablation in the treatment of patients with oligometastatic non-small-cell lung cancer: a retrospective study.
- Author
-
Wei, Zhigang, Ye, Xin, Yang, Xia, Huang, Guanghui, Li, Wenhong, Han, Xiaoying, Wang, Jiao, Meng, Min, Ni, Yang, and Li, Qingyu
- Published
- 2019
- Full Text
- View/download PDF
32. Invasive pulmonary aspergillosis secondary to microwave ablation: a multicenter retrospective study.
- Author
-
Huang, Guanghui, Ye, Xin, Yang, Xia, Wang, Chuntang, Zhang, Licheng, Ji, Guangdong, Zhang, Kaixian, Wang, Huili, Zheng, Aimin, Li, Wenhong, Wang, Jiao, Han, Xiaoying, Wei, Zhigang, Meng, Min, and Ni, Yang
- Subjects
- *
PULMONARY aspergillosis , *BRONCHIAL arteries , *HEALTH facilities , *LUNG cancer , *DEMOGRAPHIC characteristics , *RETROSPECTIVE studies - Abstract
Purpose: Invasive pulmonary aspergillosis (IPA) is a life-threatening complication of microwave ablation (MWA) during the treatment of primary or metastatic lung tumors. The purpose of this study was to investigate the clinical, radiological and demographic characteristics and treatment responses of patients with IPA after MWA. Materials and methods: From January 2011 to January 2016, all patients who were treated by MWA of their lung tumors from six health institutions were enrolled in this study. Patients with IPA secondary to MWA were identified and retrospectively evaluated for predisposing factors, clinical treatment, and outcome. Results: The incidence of IPA secondary to lung MWA was 1.44% (23/1596). Of the 23 patients who developed IPA, six died as a consequence, resulting in a high mortality rate of 26.1%. Using computed tomography (CT), pulmonary cavitation was the most common finding and occurred in 87.0% (20/23) of the patients. Sudden massive hemoptysis was responsible for one-third of the deaths (2/6). Most patients (22/23) received voriconazole as an initial treatment, and six patients with huge cavities underwent intracavitary lavage. Finally, 17 patients (73.9%) achieved treatment success. Conclusions: Lung MWA may be an additional host risk factor for IPA, particularly in elderly patients with underlying diseases and in patients who have recently undergone chemotherapy. Early and accurate diagnosis of IPA after MWA is critical for patient prognosis. Voriconazole should be given as the first-line treatment as early as possible. Bronchial artery embolization or intracavitary lavage may be required in some patients. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
33. Programmed death-ligand 1 expression and CD8+ tumor-infiltrating lymphocytes in advanced non-small cell lung cancer treated with microwave ablation and chemotherapy.
- Author
-
Wei, Zhigang, Zhan, Xuemei, Fan, Linlin, Ye, Xin, Yang, Xia, Huang, Guanghui, Li, Wenhong, Wang, Jiao, Han, Xiaoying, Meng, Min, Ni, Yang, and Li, Qingyu
- Subjects
NON-small-cell lung carcinoma ,LYMPHOCYTES ,CANCER chemotherapy ,MICROWAVES - Abstract
Background: Programmed death-ligand 1 (PD-L1) and CD8+ tumor-infiltrating lymphocytes (TILs) were associated with non-small cell lung cancer (NSCLC). We conducted this study to evaluate the correlation between PD-L1 or CD8+ TILs expression and MWA or survival in advanced NSCLC patients treated with microwave ablation (MWA) plus chemotherapy. Methods: Previously untreated, pathologically verified advanced NSCLC patients with adequate tissues for the analysis of PD-L1 expression and the presence of CD8+ TILs were retrospectively enrolled. None of the patients had sensitive mutations, and therefore, they were treated with MWA of the primary tumors followed by chemotherapy. Results: A total of 51 patients were enrolled. PD-L1 expression and the presence of CD8+ TILs were identified in 31 (60.8%) and 9 (17.6%) patients, respectively. PD-L1 expression and CD8+ TILs had no correlation with baseline characteristics, the response to chemotherapy or MWA. Patients with PD-L1 expression had similar progression-free survival (PFS: 7.9 months for PD-L1-positive vs. 5.8 months for PD-L1-negative; p = .660) and overall survival (OS: 18.7 months for PD-L1-positive vs. 15.2 months for PD-L1-negative; p = .901). Patients with CD8+ TIL expression did not show superior PFS (CD8+ TIL vs. CD8- TIL, 8.0 vs. 6.2 months, p = .435) or OS (CD8+ TIL vs. CD8- TIL, 20.5 vs. 16.9 months, p = .653). Conclusion: PD-L1 expression and the presence of CD8+ TILs could predict neither the patients' response to chemotherapy or MWA nor survival in advanced NSCLC patients treated with MWA plus chemotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
34. Microwave ablation followed by immediate biopsy in the treatment of non-small cell lung cancer.
- Author
-
Wei, Zhigang, Wang, Qiaoxia, Ye, Xin, Yang, Xia, Huang, Guanghui, Li, Wenhong, Wang, Jiao, Han, Xiaoying, Meng, Min, Yang, Ni, and Li, Qingyu
- Subjects
NON-small-cell lung carcinoma ,MICROWAVES ,ABLATION techniques ,CANCER treatment ,TREATMENT effectiveness ,PATIENT safety ,BIOPSY ,PATHOLOGY - Abstract
Background: To evaluate the efficacy and safety of microwave ablation (MWA) followed by immediate biopsy in the treatment of non-small cell lung cancer (NSCLC) and to clarify whether pathology changes can predict treatment responses and patient survival. Methods: Patients with pathologically confirmed NSCLC pre-ablation were treated with MWA, and immediate biopsy was carried out right after ablation in one procedure. Pathology changes were categorized according to the pre- and postablation pathology: Group A, same histology type; Group B, paired histology type with burning degeneration; Group C, no definite histology type; Group D, no definite cancer cells. The internal correlations between pathology changes and baseline characteristics, responses to MWA and survival were evaluated. Results: A total of 68 patients were enrolled in the study, of which 19, 28, 11 and 10 patients were classified into Group A, Group B, Group C and Group D, respectively. In total, 85.3 and 69.1% patients were diagnosed with malignant tumors and the same pathology type, respectively. No significant difference in clinical-pathologic characteristics or response to MWA between the groups was observed. Upon combining Groups A, B and C, Group D exhibited longer progression-free survival (PFS) (Groups A + B + C versus Group D, 11.7 months, 95% CI 9.6-13.7 versus 26.6 months, 95% CI 19.0-34.2, p = .253) and overall survival (OS) (15.9 months, 95% CI 14.2-17.5, versus 29.8 months, 95% CI, 24.3-35.3, p = .395), although no significant differences were observed. Complications were identified in 63 (92.6%), of which 17 (25.0%) patients had major complications. Conclusions: Immediate biopsy post-MWA can distinguish cancer cells or histology types in most cases of NSCLC. However, pathology changes pre- and postablation could not predict the response to MWA and patient survival. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
35. The efficacy and safety of microwave ablation in patients with retroperitoneal metastases.
- Author
-
Wei, Zhigang, Ye, Xin, Yang, Xia, Zheng, Aimin, Huang, Guanghui, Li, Wenhong, Wang, Jiao, Han, Xiaoying, Meng, Min, Ni, Yang, and Dong, Shenming
- Subjects
- *
CANCER treatment , *METASTASIS , *ABLATION techniques , *TREATMENT effectiveness , *ADVERSE health care events - Abstract
Background: Retroperitoneal metastases are common, and most present with symptoms; however, treatments for this condition are limited. This retrospective study verified the efficacy and safety of microwave ablation (MWA) in retroperitoneal metastases patients. Methods: Patients with pathologically confirmed malignant carcinoma and imaging showing retroperitoneal metastases were enrolled and underwent MWA. The end-points included objective response rate, time to local progression (TTLP), overall survival, visual analogue scale (VAS) score, dose of morphine pre- and post-ablation and complications. Results: Twenty-three patients were enrolled. The mean tumour diameter was 3.6 cm. Altogether, 29 tumour sites in 23 patients were ablated during 23 procedures; technical success was achieved in all 23 patients. The objective response and disease control rates were 95.7% and 100.0%, respectively. The mean TTLP and median OS were 22.8 months (95% CI: 16.1-29.6 months) and 10.6 months (95% CI: 7.4-13.8 months), respectively. In 13 patients with symptoms, the VAS values before ablation and 48 h, 1 month, 2 months, 3 months and 6 months after ablation were 5.38, 2.77 (p = 0.015), 2.15 (p = 0.001), 2.17 (p = 0.001), 1.40 (p = 0.000) and 1.71 (p = 0.006), respectively. The corresponding morphine doses were 76.9 mg, 70.7 mg (p = 0.584), 50.7 mg (p = 0.031), 55.0 mg (p = 0.097), 46.0 mg (p = 0.057) and 40.0 mg (p = 0.363), respectively. No ablation-associated mortality was observed. Major complications, minor complications and adverse events were observed in eight (34.8%), five (21.7%) and four (17.4%) patients, respectively. Conclusion: MWA for the treatment of retroperitoneal metastases was effective and the complications were common. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
36. Computed tomography-guided percutaneous microwave ablation for treatment of peripheral ground-glass opacity-Lung adenocarcinoma: A pilot study.
- Author
-
Yang, Xia, Ye, Xin, Lin, Zhengyu, Jin, Yong, Zhang, Kaixian, Dong, Yuting, Yu, Guohua, Ren, Haipeng, Fan, Weijun, Chen, Jin, Lin, Qingfeng, Huang, Guanghui, Wei, Zhigang, Ni, Yang, Li, Wenhong, Han, Xiaoying, Meng, Min, Wang, Jiao, and Li, Yuliang
- Subjects
- *
LUNG cancer , *COMPUTED tomography , *MICROWAVE hyperthermia therapy , *ADENOCARCINOMA , *CANCER treatment , *SURVIVAL analysis (Biometry) , *PATIENTS , *MICROWAVES , *TREATMENT of lung tumors , *CATHETER ablation , *LONGITUDINAL method , *LUNG tumors , *NEEDLE biopsy , *COMORBIDITY , *PILOT projects , *TREATMENT effectiveness , *RETROSPECTIVE studies , *THERAPEUTICS - Abstract
Purpose: The purpose of the study is to retrospectively evaluate the safety and efficacy of microwave ablation (MWA) for the treatment of ground-glass opacity (GGO)-lung adenocarcinoma.Materials and Methods: From December 2013 to June 2017, a total of 51 patients (22 males and 29 females, mean age of 69.4 ± 10.1 years) were included in this study, with 51 lung adenocarcinoma lesions showing GGO (mean long-axis diameter of 18.7 ± 6.05 mm). They received a total of 52 sessions of percutaneous computed tomography-guided (CT-guided) MWA. First, lung adenocarcinoma with GGO was histologically defined by needle biopsy under the guidance of CT. Second, the efficacy of CT-guided MWA was analyzed, including the feasibility, safety, 3 years local progression-free survival (LPFS), 3 years disease-specific survival, and 3 years overall survival (OS). Final, complications after MWA were also summarized.Results: The technical success rate was 100%, without MWA procedure-related death. At the median follow-up period (27.02, range: 7-45 months), the rates of 3 years LPFS, cancer-specific survival, and OS were 98%, 100%, and 96%, respectively. The complications after MWA included pneumothorax (48.1%, 25/52), hemoptysis (28.8%, 14/52), pleural effusion (23.1%, 12/52), and pulmonary infection (7.7%, 4/52).Conclusions: CT-guided percutaneous MWA was a feasible, safe, and effective therapeutic approach for treating GGO-lung adenocarcinoma. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
37. Expert consensus workshop report: Guidelines for thermal ablation of primary and metastatic lung tumors (2018 edition).
- Author
-
Ye, Xin, Fan, Weijun, Wang, Hui, Wang, Junjie, Wang, Zhongmin, Gu, Shanzhi, Feng, Weijian, Zhuang, Yiping, Liu, Baodong, Li, Xiaoguang, Li, Yuliang, Li, Chengli, Xiao, Yueyong, Yang, Po, Yang, Xia, Yang, Wuwei, Chen, Junhui, Zhang, Rong, Lin, Zhengyu, and Meng, Zhiqiang
- Subjects
- *
LUNG cancer , *TREATMENT of lung tumors , *LASER therapy , *CATHETER ablation , *SURGICAL complications , *CRYOSURGERY - Abstract
Although surgical resection with curative intent is the main therapy for both primary and metastatic lung tumors, about 80% of lung cancers cannot be removed by surgery. Because most patients with unresectable lung cancer only receive limited benefits from traditional radiotherapy and chemotherapy, many novel local treatment modalities have emerged including local ablation therapy. The Minimally Invasive Treatment of Lung Cancer Branch, Professional Committee of Minimally Invasive Treatment of Cancer of the Chinese Anti-Cancer Association and Committee on Tumor Ablations, Chinese College of Interventionalists have organized multidisciplinary experts to develop guidelines for this treatment modality. These guidelines aim at standardizing thermal ablation procedures, describing the indications for candidates, assessing outcomes, and preventing postablation complications. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
38. Computed tomography-guided percutaneous microwave ablation of early stage non-small cell lung cancer in a pneumonectomy patient.
- Author
-
Wei, Zhigang, Wang, Jiao, Ye, Xin, Yang, Xia, and Huang, Guanghui
- Subjects
MICROWAVES ,CANCER relapse ,BIOPSY ,COMPUTED tomography ,LUNG cancer ,LUNG tumors ,PNEUMONECTOMY ,SQUAMOUS cell carcinoma ,ABLATION techniques ,DIAGNOSIS ,THERAPEUTICS - Abstract
A squamous cell lung cancer patient was treated with pneumonectomy. A recurrent lung cancer (adenocarcinoma) was found 45 months later and successfully biopsied and treated with microwave ablation. After 18 months of follow up, no evidence of tumor recurrence was observed. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
39. Safety and efficacy of percutaneous biopsy and microwave ablation in patients with pulmonary nodules on antithrombotic therapy: A study with rivaroxaban bridging.
- Author
-
Wang, Nan, Xue, Tianyu, Zheng, Wenwen, Shao, Zhongying, Liu, Zhuang, Dai, Faliang, Xie, Qi, Sang, Jing, and Ye, Xin
- Subjects
- *
FIBRINOLYTIC agents , *PULMONARY nodules , *TREATMENT effectiveness , *TECHNICAL information , *RIVAROXABAN - Abstract
Background Methods Results Conclusions To evaluate the safety and efficacy of percutaneous biopsy and microwave ablation (B + MWA) in patients with pulmonary nodules (PNs) who are receiving antithrombotic therapy by rivaroxaban as bridging therapy.The study comprised 187 patients with PNs who underwent 187 B + MWA sessions from January 1, 2020, to December 31, 2021. The enrolled patients were divided into two groups: Group A, who received antithrombotic therapy five days before the procedure and received rivaroxaban as a bridging drug during hospitalization, and group B, who had no antithrombotic treatment. Information about the technical success rate, positive biopsy rate, complete ablative rate, and major complications were collected and analyzed.Group A comprised 53 patients and group B comprised 134 patients. The technical success rate was 100% in both groups. The positive biopsy rates were 88.68% and 91.04%, respectively (p = 0.6211, X2 = 0.2443). In groups A and B, the complete ablative rates at 6, 12, and 24 months were 100.0% versus 99.25%, 96.23% versus 96.27%, and 88.68% versus 89.55%, respectively. There were no significant differences in bleeding and thrombotic complications between the two groups. No grade 5 complications occurred.It is generally considered safe and effective that patients who are on antithrombotic therapy by rivaroxaban as bridging to undergo B + MWA for treating PNs. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
40. CT‐guided microwave ablation in patients with lung metastases from breast cancer.
- Author
-
Meng, Min, Han, Xiaoying, Li, Wenhong, Huang, Guanghui, Ni, Yang, Wang, Jiao, Zhang, Tiehong, Dai, Jianjian, Zou, Zhigeng, Yang, Xia, and Ye, Xin
- Abstract
Background Methods Results Conclusion Computed tomography (CT)‐guided percutaneous microwave ablation (MWA) is a very common ablation method that shows a good local tumor control rate in primary and secondary lung tumors. At present, few reports have explored the safety and efficacy of MWA for lung metastases from breast cancer.From January 2012 to January 2018, 32 breast cancer patients with 46 pulmonary metastases received CT‐guided percutaneous MWA. The study was approved by the local institutional review board. The clinical efficacy and complications of MWA were investigated.The median follow‐up time was 32 months and the main effective rate was 97.8% (45/46). Five of 46 lesions had local progression (10.9%), with a median progression time of 10 months. The 1‐, 3‐, and 5‐year overall survival (OS) rates were 96.9%, 53.3%, and 17.8%, respectively. The median OS time was 36 months. Among 46 MWA treatments, 11 (23.9%) had massive pneumothorax, two (4.3%) had massive pleural effusion, and two (4.3%) had a pulmonary infection.CT‐guided percutaneous MWA may be safe and effective for treating lung metastases from breast cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.